Eupraxia Pharmaceuticals Inc.

EPRX.TOTSXHealthcare● Active

$8.49

+$0.16(+1.92%)

Market Cap$305109655

P/E Ratio—

52W High$12.86

52W Low$5.2

Avg Volume58K

Open$8.50

Beta1.48

Free Cash Flow Financials Revenue

Eupraxia Pharmaceuticals Inc. (EPRX.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

EPRX.TO · free cash flow · updated Jun 8, 2026

Core FCF metrics

EPRX.TO · FCF · TTM · margin & CAGR

Free cash flow was −$29.7M for FY2025 (fiscal year ending 2025-12-31), up 1.5% year-over-year

FY2025 Free Cash Flow−$29.7M▲ +1.5% YoY

Trailing 12M (TTM)−$32.1Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

EPRX.TO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$29.1M(1M)−$29.7M▲ +1.5%—

FY2024−$30.0M(0M)−$30.1M▼ 42.7%—

FY2023−$20.7M(0M)−$21.1M▼ 10.5%—

FY2022−$18.8M(0M)−$19.1M▼ 26.6%—

FY2021−$14.6M(0M)−$15.1M▼ 3631.7%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

EPRX.TO · P/FCF · FCF yield · FCF per share

Eupraxia Pharmaceuticals Inc. (EPRX.TO) reported negative free cash flow of −$0.03B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

EPRX.TO · cash flow statement · operating / investing / financing

For FY2025, Eupraxia Pharmaceuticals Inc. generated −$29.1M in operating cash flow and spent 1M in capital expenditures, yielding −$29.7M in free cash flow.

Operating Activities

−$29.1M

Cash from core business operations

2025-12-31

Investing Activities

−$0.6M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$77.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$29.1M) − |CapEx| (1M) = FCF (−$29.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

EPRX.TO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Eupraxia Pharmaceuticals Inc.YOU

EPRX.TO

−$29.7M+1.5%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Eupraxia Pharmaceuticals Inc. (EPRX.TO) reported free cash flow of −$29.7M for FY2025 (fiscal year ending 2025-12-31), up 1.5% year-over-year.

Eupraxia Pharmaceuticals Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 9 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

EPRX.TO free cash flow · 8 questions

Eupraxia Pharmaceuticals Inc. free cash flow was −$29.7M for FY2025, up 1.5% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$32.1M.

EPRX.TO free cash flowEPRX.TO FCFEPRX.TO FCF 2025EPRX.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Eupraxia Pharmaceuticals Inc. · Eupraxia Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026